RSS
|
Login
|
Register
HOME
SPECIALTY
Hematology-Oncology
Long Term Care
Nurse Practitioners
OB/GYN
Pharmacists
Physician Assistants
Primary Care Physicians
Residents
Urologists
THERAPEUTIC CATEGORIES
BRAND
GENERIC
COMPARE
NEWS
Drug News
Drugs in the Pipeline
Drug Safety Alerts and Recalls
New Drug Products
Polls & Surveys
Newsletters
News from Haymarket Journals
RESOURCES
Alerts (Sponsored)
Clinical Charts
Common Medical Abbreviations
Company
Drug Monograph Format
FDA Orange Book
Pharmacology Notes
Professional Associations
Video
Blogs
MPR Publications
Customer Service
Online Banner Ad Specs
Subscribe
DOWNLOAD
CME
JOBS
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Home
>
Therapeutic Categories
>
Ob/Gyn
> Miscellaneous Ob/Gyn conditions
Ob/Gyn
»
Miscellaneous Ob/Gyn conditions
Select All |
Compare
|
Add to Clipboard
|
View Clipboard
Name
Compare
DEPO-SUBQ PROVERA
compare
LUPRON DEPOT 3.75mg
compare
LUPRON DEPOT-3 MONTH 11.25mg
compare
METHERGINE
compare
METHERGINE INJECTION
compare
MIFEPREX
compare
MIRENA
compare
Most Popular
Most Emailed
Most Recent
FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
Kapidex to be marketed under new trade name Dexilant
Generic tamsulosin available for benign prostatic hyperplasia (BPH)
Hizentra approved for primary immunodeficiency
Norditropin FlexPro pen approved for growth hormone treatment
Xiaflex available for Dupuytren's contracture
Trelstar 22.5mg approved for palliative treatment of prostate cancer
Pediaderm HC Complete Kit available for atopic dermatitis
New Product: SAPHRIS
®
(asenapine) Sublingual Tablets
Botox approved for upper limb spasticity
FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
Recommended Adult Immunization Schedule
Prevnar 13 pneumococcal disease vaccine approved
Xiaflex available for Dupuytren's contracture
Hizentra approved for primary immunodeficiency
Kapidex to be marketed under new trade name Dexilant
Ampyra available for multiple sclerosis patients
FDA grants priority review to Tasigna for newly diagnosed chronic myeloid leukemia
FDA accepts NDA for JZP-6, a treatment for fibromyalgia
Rituxan approved for chronic lymphocytic leukemia
Bowel Cleansers
Neosalus Cream available for dermatitis
FDA warns of reduced Plavix efficacy in poor metabolizers
Five-day dosing regimen for Dacogen approved for myelodysplastic syndromes (MDS)
FDA reviews atypical subtrochanteric femur fractures risk with oral bisphosphonates
Trelstar 22.5mg approved for palliative treatment of prostate cancer
FDA accepts NDA for lurasidone, a treatment for schizophrenia
FDA warns of intravascular hemolysis risk with WinRho SDF
Botox approved for upper limb spasticity
New Product: SAPHRIS
®
(asenapine) Sublingual Tablets
Sponsored Links